CBER 对 AAV 基因治疗 IND 申请的全面分析
A comprehensive analysis of CBER experience with AAV gene therapy IND submissions
从 1995 年到 2025 年,美国 FDA 的生物制品评估与研究中心(CBER)收到的腺相关病毒(AAV)基因治疗 IND 申请数量显著增长。分析指出,监管暂停的主要原因是常见的技术问题,这些应成为成功产品开发的考虑因素。
- Comment
- Published: 12 November 2026
Nature Biotechnology (2026) Cite this article
An analysis of Investigational New Drug (IND) submissions to the US Food and Drug Administration (FDA) from 1995 to 2025 reveals a rapid growth in adeno-associated virus (AAV) development over three decades and highlights common reasons for regulatory holds that should be considered for successful product development.
This is a preview of subscription content, access via your institution
Access options
Access through your institution
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
32.70 € / 30 days cancel any time
Buy this article
- Purchase on SpringerLink
- Instant access to the full article PDF.
39,95 €
Prices may be subject to local taxes which are calculated during checkout
Additional access options:
References
Bulcha, J. T., Wang, Y., Ma, H., Tai, P. W. L. & Gao, G. Signal Transduct. Target. Ther. 6, 53 (2021).
Wang, J.-H., Gessler, D. J., Zhan, W., Gallagher, T. L. & Gao, G. Signal Transduct. Target. Ther. 9, 78 (2024).
Li, C. & Samulski, R. J. Nat. Rev. Genet. 21, 255–272 (2020).
Duan, D. et al. J. Virol. 72, 8568–8577 (1998).
Dong, B., Nakai, H. & Xiao, W. Mol. Ther. 18, 87–92 (2010).
Gao, G. et al. J. Virol. 78, 6381–6388 (2004).
Maguire, A. M. et al. N. Engl. J. Med. 358, 2240–2248 (2008).
Lapteva, L., Purohit-Sheth, T., Serabian, M. & Puri, R. K. Mol. Ther. Methods Clin. Dev. 19, 387–397 (2020).
Nathwani, A. C. et al. N. Engl. J. Med. 371, 1994–2004 (2014).
Mingozzi, F. & High, K. A. Blood 122, 23–36 (2013).
Russell, S. et al. Lancet 390, 849–860 (2017).
Foust, K. D. et al. Nat. Biotechnol. 27, 59–65 (2009).
Pacak, C. A. et al. Circ. Res. 99, e3–9 (2006).
Srivastava, A. Curr. Opin. Virol. 21, 75–80 (2016).
Wang, L. et al. Mol. Ther. 18, 118–125 (2010).
Grimm, D. et al. J. Virol. 82, 5887–5911 (2008).
Hinderer, C. et al. Hum. Gene Ther. 29, 285–298 (2018).
Laforet, G. A. Hum. Gene Ther. 36, 64–76 (2025).
Acknowledgements
We thank Z. Ye, K. Schultz, S. Butler, A. Harmon, R. Vatsan, D. Gavin, A. Harvan and P. Kurs for valuable review, feedback and advice. The opinions presented in this article are those of the authors and do not necessarily represent the views or policies of FDA. This article does not include all programs, policies and incentives available for development of novel therapies for rare diseases.
Author information
Authors and Affiliations
Office of Therapeutic Products, Center for Biologics Evaluation and Research, US Food and Drug Administration, Silver Spring, MD, USA
Sojin Bing, Takele Argaw, Megha Kaushal & Ronit Mazor
Authors
- Sojin Bing
- Takele Argaw
- Megha Kaushal
- Ronit Mazor
Corresponding author
Correspondence to Ronit Mazor.
Ethics declarations
Competing interests
All authors are employed by the US Food and Drug Administration.
About this article
Cite this article
Bing, S., Argaw, T., Kaushal, M. et al. A comprehensive analysis of CBER experience with AAV gene therapy IND submissions. Nat Biotechnol (2026). https://doi.org/10.1038/s41587-026-03378-9
Published: 12 November 2026
Version of record: 12 November 2026
DOI: https://doi.org/10.1038/s41587-026-03378-9
来源:Nature 健康护理主题 · nature.com